Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GMMG-HD9/DSMM XVIII iberdomide ± isatuximab maintenance post-ASCT
2023-507402-13-00Phase 3Authorised
- Sponsor
- Heidelberg University Hospital
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised trial in multiple myeloma (MM) comparing Iberdomide maintenance with Iberdomide plus isatuximab maintenance (2 arms). Primary endpoint: NGF-MRD negativity rate at 2 years. Planned start Feb 2024; status: authorised.
02
Drugs
iberdomideisatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-507402-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507402-13-00.